MOBARTOL
Food supplement declared in France, decision dated 24 October 2026
MOBARTOL (IPHYM) is a food supplement declared in France. Status: declared in France, may be marketed. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- IPHYM
- Food business operator placing the product on the market
- Laboratoires IPHYM
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 4 gelules par jour
- Directions for use
- Prendre 2 gélules, matin et soir.
- Intended populations
- Men and women aged 18 and over, Men, Women
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Allergy to salicylate derivatives, Pregnant women, Kidney failure, Heart problems, Taking anticoagulants, Ulcer (stomach or duodenum)
- Objectives stated by the manufacturer (these are not authorised claims)
- Joints
Declaration 380396, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Harpagophytum procumbens | Racine | Extrait sec aqueux | 400 mg |
| Ribes nigrum L. | Feuille | Extrait sec aqueux | 200 mg |
| Filipendula ulmaria (L.) Maxim. | Sommités fleuries | Poudre (de plantes séchées ou broyées) | 80 mg |
Additives
E553b, Hydroxypropyl Méthyl Cellulose
Other ingredients
maltodextrine
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Ne pas dépasser la dose journalière recommandée. Ne se substitue pas à un régime alimentaire varié et sera utilisé dans le cadre d'un mode de vie sain. Ne pas laisser à la portée des jeunes enfants. Déconseillé en cas d’ulcère gastro-duodénal ou de troubles biliaires (calculs biliaires), en cas d’insuffisance cardiaque ou rénale œdémateuses, chez les personnes sous traitement anti-coagulant, en cas d’hypersensibilité aux salicylés (aspirine). Réservé aux adultes. Déconseillé aux femmes enceintes ou allaitantes.
Regulatory points
- Conditions légales
Filipendula ulmaria (L.) Maxim.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux personnes souffrant d'allergie aux dérivés salicylés.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Harpagophytum procumbens
Read the warning, when it applies and the studies cited
DEVIL'S CLAW - HARPAGOPHYTUM
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- MOBARTOL IPHYM, declared in 2019, earlier declaration, replaced by the 2026 declaration : different composition: 1 ingredient(s) added, 2 missing
Brand : IPHYM
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.